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Abstract
Cardiovascular disease affects 1.6 million Canadians, of whom one-third have heart failure
(HF). HF is diagnosed by imaging investigations and detection of circulating biomarkers. Most
of the current imaging strategies study morphologic and gross functional changes, but fall short
of imaging molecular abnormalities associated with HF. Biomarkers offer molecular targets;
however, clinical biomarkers circulate systemically and are not cardiac-specific. Thus, there is
critical need for a biomarker that is endogenous to myocardial tissues. The growth hormone
secretagogue receptor 1a (GHSR1a), which binds the hormone ghrelin, is expressed by
cardiomyocytes and is elevated in HF patients. This study characterized the specificity of the
novel tracer [1-Nal4, Lys5(4-[18F]-FB)]G-7039 to target GHSR1a using Positron Emission
Tomography (PET). In vitro analysis of probe specificity by cellular uptake determined that
binding was independent of receptor expression, which was confirmed by in vivo PET imaging
in GHSR1a-wildtype (wt) and -knockout (ghsr-/-) mice. Ex vivo biodistribution comparing
specificity and effects of nutritional state showed that [1-Nal4, Lys5(4-[18F]-FB)]G-7039 did
not distribute to the heart and uptake was independent of circulating ghrelin levels. Although
[1-Nal4, Lys5(4-[18F]-FB)]G-7039 demonstrated in vitro stability, negligible cardiac uptake
and high uptake in the liver, intestines and kidneys within 1 h post-injection indicated rapid
probe elimination through hepatobiliary and renal mechanisms, possibly explained by a highly
lipophilic tracer. Analysis of cardiac GHSR1a expression and metabolic markers by
fluorescence microscopy in fasted, fed, wt and ghsr-/- mice suggests that there may be a
ghrelin/GHSR1a system in the heart that is regulated independently of systemic
ghrelin/GHSR1a, and that GHSR1a does not play a significant role in cardiac metabolism in
healthy mice. In vitro stability and cellular uptake, ex vivo biodistribution and in vivo imaging
conducted in this study present a step towards characterizing a suitable GHSR1a PET tracer
that may be used to detect HF.
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Chapter 1

1

Introduction

Diseases that affect the heart muscle are collectively referred to as cardiomyopathies. The
hallmarks of cardiomyopathies include cardiomegaly, heart wall thickening, increased
rigidity, ischemia, inflammation, and, in some cases, scar tissue formation. The heart grows
weaker as cardiomyopathy escalates, which commonly results in the clinical syndrome of
heart failure. Significant advancements in treating and caring for patients with
cardiomyopathy, particularly acute myocardial infarction, have reduced incidence of death,
leaving survivors susceptible to secondary cardiovascular events and developing heart
failure1,2.

1.1 Congestive Heart Failure
Heart failure (HF) is characterized by the inability of the heart to provide adequate cardiac
output to meet the metabolic demands of the body. It results in reduced ventricular
function. Consequently, the heart is unable to adequately perfuse body tissues because of
impaired systolic function (termed HF with reduced ejection fraction, where the ventricles
do not eject blood efficiently), diastolic function (termed HF with preserved ejection
fraction, where the ventricles are unable to fill effectively) or a combination of the two.
This leads to elevated diastolic pressures and fluid backup in the lungs and peripheral
tissues. Additionally, kidney function and perfusion is reduced, aggravating fluid backup
and further exacerbating fluid retention. The body responds with compensatory measures,
including increased heart rate, sympathetic activation, as well as hormonal regulation of
blood volume and pressure, such as activation of the renin-angiotensin-aldosterone system
(RAAS). Under chronic conditions, HF severity develops marked physiologic and
molecular changes, such as natriuretic peptide release and ventricular hypertrophy to raise
the force and volume of blood ejected. The congestive nature of HF manifests as chronic
fluid retention and increased venous pressure. Patients experience shortness of breath,
fatigue, and peripheral edema.
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HF generates significant economic burden on the healthcare system and personal
challenges for the patients who suffer from it. A cost analysis of the financial burden of
admissions for HF between 2004 to 2013 found that admissions where HF is the primary
diagnosis place a $482 M yearly burden on Canadian health services, and these costs are
expected to increase to approximately $722 M by 2030. Accounting for admissions where
HF is the secondary diagnosis results in a projected total cost of $2.8 B in 20303. HF is also
a significant contributor to morbidity and mortality. HF patients have the highest
readmission rates of all chronic illness patients in Canada and the second highest
readmission volume. Twenty-one percent of HF patients are readmitted to inpatient care
within 30 days4. Admission rates have increased in the past decade and are expected to
continue to increase. It is thought that improvements in therapeutic interventions and
management strategies for acute cases contribute to increased survival rates of patients with
high probability of developing impaired cardiac function and eventually HF. The incidence
rates of HF are also expected to increase in the coming years due to an aging population5
and improvements to care that increase survival rates from myocardial infarctions6.

1.1.1

Functional Classifications of HF Evolution

The New York Heart Association (NYHA)7 classification method is the most prevalent
system used to classify HF. It is based on clinical severity and prognosis. The
classifications range from mild, asymptomatic HF without limitations to physical activity
(stage I) to severe HF with the inability to undergo any form of physical exercise without
discomfort (stage IV).
A more recent classification method was devised by the American College of Cardiology
(ACC) and American Heart Association (AHA)8 which focuses on the evolution of the
disease. The ACC/AHA classification system connects risk factors and structural changes
to the development of HF. Patients range from stage A, where high risk is present without
structural evidence, to stage D, comprising of patients with end-stage disease requiring
extensive intervention. Patients in the intermediate stage B have structural dysfunction
without symptoms and those in stage C have had or currently have symptoms associated
with underlying structural dysfunction. The ACC/AHA classification system emphasizes
what others have theorized9: that therapeutic action prior to developing structural
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aberrations or early in disease evolution (ie. Stages A and B) can reduce morbidity and
mortality linked to HF.
Although these methods are popular and relatable for patients, they are limited by the
ability of the patient to recognize symptoms and refer to a physician. Moreover, the stages
with mild symptoms (NYHA stages I and II) do not present severely enough to motivate
medical consultation. Meanwhile, cardiac dysfunction progresses absent intervention.

1.1.2

Etiology and Pathophysiology

HF is a common terminal state of many cardiovascular diseases. Its etiology involves a
significant loss of viable cardiomyocytes resulting from damage caused by an insult to the
heart. The resultant effect is a reduction in cardiac output, reduced tissue perfusion, and
ventricular remodeling that occur over time10. The most prevalent etiologies are myocyte
loss due to myocardial infarction, hypertension, and chronic ischemia. Less common
causes include diabetes, bacterial or viral infection, connective tissue diseases, and valvular
disease. Some studies have found that a significant portion of patients present with HF of
unknown etiology11,12, further underscoring the need to establish an understanding of
pathogenesis and pathophysiology.

1.1.3

Cardiac Metabolism

It is established that most HF pathophysiology can be attributed to the body’s own
compensatory mechanisms10,13. To maintain tissue perfusion caused by decreased mean
arterial pressure (MAP) in HF, the body compensates by increasing cardiac output (CO)
and/or total peripheral resistance (TPR) through several mechanisms. These include
sympathetic autonomic activation, neurohormonal regulation, and ventricular remodeling.
Along with hormonal and remodeling changes, molecular aberrations in HF include
alterations to Ca2+ signaling and altered metabolic pathways.
Cardiac output is a product of the heart rate and the stroke volume (the volume of blood
ejected from the heart during systole). Stroke volume is affected by the myocardial stretch
during the relaxation phase of the cardiac cycle at the end of diastole (the preload). This
relaxation is related to changes in Ca2+ signaling in the heart. SERCA2a is an endoplasmic
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reticulum-bound Ca2+ transporter which shuttles Ca2+ from the cytoplasm to the
sarcoplasmic reticulum (SR) in cardiomyocytes. The actions of SERCA2a play a role in
relaxation, and thus affect the preload. SERCA2a downregulation has been observed in
models of HF and patients with HF14, and potentially contributes to aberrant diastolic
function observed in HF patients.
To fuel contractions and ion pumps like SERCA2a, the heart must access appropriate
energy sources. Circulating lipids are the primary energy source for cardiomyocytes and
are transported into cardiomyocytes via the fatty acid (FA) transporter CD36. CD36
expression is reduced in patients with HF and it has been implicated in contributing to Ca2+
handling15. A reduction in CD36 under chronic ischemic conditions results in changeover
from lipids to glucose as the primary metabolic substrate in the myocardium. This is
exemplified by upregulation of the insulin-dependent glucose transporter, GLUT416. This
is especially advantageous under anaerobic conditions, like ischemia, where it is postulated
that the switchover is favoured because glucose metabolism is less oxygen-demanding than
lipid metabolism16. These cellular changes occur prior to presentation of outward
symptoms in HF patients and provide insight into the molecular progression in the
pathogenesis of HF.
Current best practices and interventions fall short of halting or even stalling HF evolution,
as shown by a study that found no improvement in prognosis for patients with HF in
Ontario over a ten year period17. Patients continue to deteriorate to the point where cardiac
transplantation is necessary or death occurs. Understanding the molecular mechanisms
underlying the pathogenesis and pathophysiology of HF could potentially direct the
development of novel therapies and diagnostic imaging techniques.

1.2 Diagnosis of Heart Failure and Diagnostic Imaging
Presently, clinicians lack an individual assessment tool to establish a HF diagnosis. Instead,
they rely on a combination of resources to definitively diagnosis the condition. Initially,
physical examination is coupled with probing into patient history. Clinical diagnosis of HF
is limited by non-specific symptoms (which do not always explicitly pertain to the heart),
insensitive tests, and few clinical characteristics that make the diagnosis obvious.
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Differential diagnoses such as pericardial diseases, liver diseases, nephrotic syndrome, and
protein losing enteropathy are possible due to the unspecific nature of the symptoms.
Adjunct to patient history and physical examination, other investigations such as
electrocardiography (ECG) can be used to indicate left ventricular hypertrophy or
arrhythmias. Major improvements in diagnosis and monitoring have come in the way of
imaging investigations, which are employed to document systolic or diastolic dysfunction.
Modern HF guidelines call for noninvasive imaging to diagnose disease and guide therapy.
The principally applied imaging modalities are radiography and echocardiography.

1.2.1

Radiography and Echocardiography

Radiography and echocardiography are commonly employed imaging tools for identifying
changes to structure and function of the heart in the more severe stages of HF. Chest
radiography is frequently used to reveal changes to heart shape and size, along with
characteristics of excess fluid, such as pulmonary congestion and pleural effusion.
Echocardiography is a powerful tool used in diagnostic imaging of HF to evaluate
ventricular size and identify valvular dysfunction and abnormalities18. Echocardiography
also affords clinicians the ability to measure ejection fraction to indicate systolic function.
Both are relatively low-cost techniques and widely available in clinical settings.
These methods are useful in their sensitivity and predictive power, but they are only
particularly adept when a patient is experiencing physical discomfort (ie. NYHA stages ≥
II; ACC/AHA stage ≥ B) and presenting outward symptoms. Echocardiography requires
expert acquisition and has high potential for intra-observer variability. Two-dimensional
echo requires imaging in the appropriate axis, and radiography also only provides a twodimensional shadow; imaging a three-dimensional object in two-dimensions reduces
quality measurements and the amount of information that can be obtained in an
investigation. There are several three-dimensional imaging modalities under active
investigation for application in imaging heart failure. Recent advances have been made in
Cardiac Magnetic Resonance Imaging (cMRI), Computed Tomography (CT), and Positron
Emission Tomography.

6

1.2.2

Cardiac MRI and CT

cMRI is a recent development in imaging heart failure and is being championed for
recovering early structural information regarding cardiomyopathies (ACC/AHA stage B).
It is a powerful diagnostic tool whose images provide three-dimensional information about
heart size, ventricular wall thickness, and functional (regarding ejection fraction in
particular) and morphological information. The latter two are especially significant in
allowing one to distinguish between health and disease19. Clinically, gadolinium contrast
can be applied to enhance images and aid in imaging myocardial fibrosis20. This method,
however, is unable to detect diffuse fibrosis, which is notable because in ischemic
cardiomyopathy, there is more diffuse than regional fibrosis21. To address this, techniques
using T1 mapping prior to and after contrast enhancement have been used to reflect diffuse
fibrosis22. Unfortunately, cMRI with gadolinium-based contrast is limited to patients who
do not have implantable devices23 and is also contraindicated in those with advanced
kidney disease, a common comorbidity seen in HF patients. Without contrast, there are
limitations in quantification because cMRI is primarily an anatomic imaging modality.
An alternative technique is CT imaging, which has seen clinical applications since the
1970s and provides high resolution morphologic and anatomic information, thus allowing
good visualization of gross anatomy. Contrast can also be used in coronary angiography
for visualization of arterial stenosis. Studies are currently being conducted in imaging of
myocardial perfusion to evaluate myocardial blood flow and cardiac lesions resulting from
coronary artery disease. In comparison with the other techniques mentioned, CT lacks
strong evidence in HF application23. Also, contrast CT must address safety issues
surrounding radiation exposure and risks for contrast-induced nephropathy (CIN) because
patients categorized into NYHA class ≥ II and with low glomerular filtration rates
(including patients with HF) are susceptible to CIN24.
Although the clinical techniques discussed are adept at providing morphological details
and characterizing overall cardiac function in HF patients, they have marked detection
limitations and are not yet equipped to predict on-set of HF prior to overt symptoms. Also,
these modalities are used for diagnosis when HF is already established. Results from other
imaging strategies that look at questions surrounding etiology, severity, and reversibility
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are important, such as the targets described in Table 1 below, and can facilitate targeted
interventions. One clinical imaging modality than can detect biochemical changes early in
the pathogenesis of HF and potentially provide answers to these questions is Positron
Emission Tomography (PET).
Table 1. Potential imaging targets early in the evolution of HF
ACC-AHA
/NYHA Stage
A/None

B/I

IMAGING TARGETS
Pathogenic Event

Possible Imaging Targets25

Left ventricular
hypertrophy and
remodeling

Microvascular perfusion imaging: endothelial
function and activity

Atherosclerosis

Imaging plaque deposition: calcification,
apoptosis, fibrosis

Ischemia

Myocardial perfusion imaging

Myocardial
infarction (MI)

Post-MI imaging of myocardial injury: apoptosis,
fibrosis, inflammation

Ventricular
dysfunction

Neurohormones of RAAS

Remodeling and
ventricular
enlargement

Remodeling and ventricular enlargement:
structural damage whilst asymptomatic
Myocardial metabolism and perfusion: FA uptake,
glucose uptake, and flow reserve

1.2.3

Positron Emission Tomography

PET is a powerful technique for non-invasive and quantitative visualization of the in vivo
distribution of a radioactive isotope (such as 11C, 13N, 15O, 18F, 68Ga, and 82Rb) integrated
into a biologically relevant molecule. It provides modest spatial resolution and high
sensitivity. Positron-emitter labeled compounds are useful for drug development and
assessing cellular uptake based on gamma-ray counting. PET is sensitive enough to detect
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very low concentrations of injected tracer (10-11 - 10-12 M)26. Radiotracers commonly used
in PET target known biochemical pathways that are the basis for metabolic processes, such
as oxygen consumption and glucose and FA transport.
For clinical HF imaging, PET is primarily used for imaging ischemia and myocardial
viability27. Identifying ischemia in HF patients is important for prognostic information and
will inform therapy decisions. Ischemia is evaluated using perfusion studies that measure
intracardiac blood flow and flow reserve, allowing for assessment of the functional impact
of coronary artery disease in HF28. A study in patients with chronic ischemic heart disease
used 13N-ammonia and 18F-FDG to measure the effectiveness of PET-myocardial perfusion
imaging in predicting HF outcomes and discovered that perfusion reserve was a better
indicator of death than ejection fraction (EF), which is a measurement of cardiac function
commonly obtained using echocardiography29. Perfusable tissue fraction can also be
observed using 13N-ammonia and C15O-PET and PET perfusion imaging has been used to
distinguish patients with dilated cardiomyopathy of unknown etiology30,31.
The most commonly used PET tracer is
synthesized by Ido et al32.

18

18

F-fluorodeoxyglucose (18F-FDG), first

F-FDG detects glucose metabolism and accumulates in

metabolizing tissues. It is the current clinical standard for detecting regional myocardial
viability and can accurately identify viability and predict functional recovery33.
Although imaging ischemia, perfusion, and viability are important in established HF, the
power of PET can be utilized to detect changes that occur in pathogenic mechanisms of HF
and to study the molecular changes underlying pathophysiology, which can be used to
monitor disease progression and to evaluate therapeutic targets and drug efficacy.
Recent developments in PET imaging of HF target molecular pathways like sympathetic
innervation and cellular processes in cardiac tissue34,35. Because the autonomic nervous
system contributes heavily to the pathophysiology observed in HF, labeled
neurotransmitter PET tracers like [11C]hydroxyephedrine (11C-HED) and [11C]epinephrine
have been used to measure the density of sympathetic nerve terminals36,37.

11

C-HED

demonstrated fast blood clearance and high heart distribution. Heart transplant patients had
significantly lower retention compared to healthy volunteers, suggesting probe sensitivity
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to neuronal activity. Another tracer,

11

C-CGP12177, targets β-adrenoreceptor expression

in the myocardium and showed reduced receptor expression in patients with dilated
cardiomyopathy38.

11

C-CGP12177 was able to predict treatment response by detecting

myocardial β-adrenoreceptor density, while echocardiography could not39. This
emphasizes the potential of PET in evaluating regional molecular changes. Probes that
target the nervous system can help guide pharmacological therapies that exert their effects
on cardiac autonomic sympathetic activity and can reveal insight into pathophysiological
mechanisms40.
Several targets are currently being studied for cardiac molecular imaging using PET. These
include imaging cellular apoptosis using

18

F-Annexin V and
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Ga-Annexin V25, and

imaging angiogenic mechanisms involved in remodeling such as the integrin αvβ3 (with
18

F-arginine-glycine-aspartic acid – 18F-RGD)40.

Apoptosis is a major mechanism of cardiomyocyte death in HF41 and subsequent
development of HF. Annexin V binds phosphatidylserine which is a phospholipid that is
exposed to the surface in apoptotic cells. Use of

18

F-Annexin V has been reported in

detection of myocardial ischemia and reperfusion injury in rats42. They described specific
cardiac localization and greater uptake in hearts of reperfusion injury rats. Another study
described differential cardiac uptake of

18

F-Annexin V in MI-induced mice with

administered Parathyroid Hormone Treatment as compared to controls, while ejection
fraction was unable to reveal differences43.

18

F-Annexin V showed promise as an

apoptosis-targeting tracer and, coupled with its short physical half-life and quick clearance
through the urinary system, it showed potential clinical utility. However, accumulation and
slow clearance in the liver hinder transition to the clinic so further development and
validation is needed.
Angiogenesis occurs following MI and is involved in ventricular remodeling. Integrins are
involved in the angiogenic process. The tracer

18

F-RGD is used to target αvβ3, a plasma

membrane glycoprotein receptor that mediates angiogenesis and is highly expressed in
activated endothelial cells25,44. 18F-RGD has shown increased uptake in a rat model of MI
prior to ventricular remodeling45, showing that αvβ3 is a possible marker of vascular

10

remodeling/angiogenesis early in the repair process.
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F-RGD has also seen clinical

application46, but requires further investigation. Future investigations should also consider
αvβ3 specificity because there are many biochemical pathways (hypertrophy, inflammation,
wound healing, fibrosis) that involve integrins and cell types (fibroblasts, cardiomyocytes,
and vascular cells) that express integrins.
These techniques have potential in guiding personalized therapy, which will allow
individual disease management to facilitate better outcomes for patients with HF. In spite
of these promising developments, HF is molecularly complex so there is still need for
development of radiotracers to image changes and distinguish various biochemical
pathways that can elucidate between benign changes and disease. None of the mentioned
tracers can individually make these distinctions reliably. Biomarkers are a useful pursuit to
obtain a more complete understanding of HF.

1.3 Heart Failure Biomarkers
Methods of identifying individuals with high risk of developing HF are urgently needed,
especially in the early stages of HF when clinical status and heart function are poor
predictors of clinical outcomes and disease stratification. After the syndrome is identified,
methods to monitor therapeutic response would be useful.
Biomarkers are objectively quantifiable indicators of biological processes. Elucidating
biomarker profiles of HF will prove useful in guiding management and therapy, and
potentially revealing the molecular mechanisms underlying the initial stages of
cardiomyopathy. Some ideal qualities of a cardiac biomarker for chronic injury are:
•

Provides accurate and repeatable measurement

•

Present in the heart at an early stage of pathogenesis

•

Cardiac specificity, where it is intrinsic to heart tissue

•

Highly sensitive, where it can report changes in cardiac function
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•

Chemically stable, where its quantity peaks to detectable levels and is not degraded
before measurements can be made

Currently, natriuretic peptides are clinically validated and established for investigating and
monitoring HF, and other biomarkers are under active investigation for potential use.

1.3.1

RAAS, Natriuretic Peptides, and Cardiac Troponins

The physiologic compensatory measures in HF are generally considered to be biomarkers
of HF10. As discussed in the Cardiac Metabolism section (1.1.3), these processes are
intended to maintain the heart’s mechanical function and tissue perfusion by regulating CO
and TPR. Some biomarkers indicate intracellular changes in cardiomyocytes relating to
stress and injury (BNP and cardiac troponins), which reduce CO. Others include
neurohormones (BNP, NT-ProBNP, ANP, renin/angiotensin II) that affect TPR.
In the early stages of HF, neurohomormonal activation contributes to maintenance of tissue
perfusion partly by increasing TPR. One pathway that is activated is the renin-angiotensinaldosterone system (RAAS). In RAAS, the enzyme renin is secreted by the kidneys in
response to reduced renal perfusion when MAP is decreased. Renin cleaves
angiotensinogen to form angiotensin I, which is converted to angiotensin II by angiotensinconverting enzyme (ACE). Angiotensin II increases vasoconstriction, thereby increasing
TPR, and promotes aldosterone release, which causes sodium retention. The net effect is
an increase in blood volume and MAP. RAAS has a fundamental role in the pathogenesis
of the renal and cardiovascular symptoms of HF10. Renin, angiotensin II, and aldosterone
are targeted in HF management using ACE inhibitors and angiotensin-receptor blockers47,
and are actively being investigated as biomarkers of HF48–50. In acute circumstances,
activation of RAAS is useful in compensation for decreased MAP, which is thought to be
why it is active in the early stages of HF. However, long term-activation leads to ventricular
remodeling, further deteriorating heart function.
The natriuretic peptide (NP) family partly consists of the hormones atrial natriuretic
peptide (ANP) and B-type natriuretic peptide (BNP). They are thought to play a protective
role in HF because they counteract the effects of chronic neurohomormal activation;
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whereas RAAS results in vasoconstriction, fluid retention and sodium reabsorption (which
leads to congestion/volume overload), NPs vasodilate, stimulate natriuresis and diuresis
(sodium and water excretion), and inhibit renin and aldosterone production51. ANP and
BNP are eliminated by two pathways: receptor-mediated internalization and metabolism,
and proteolytic degradation in the kidneys, vascular endothelium, lungs, and the heart.
ANP is cleared more quickly through both pathways. As a result, its biological circulating
half-life (3-5 min) is approximately 5-times shorter than BNP’s (~23 min) – which is even
shorter than the half-life of BNP’s N-terminal fragment, NT-proBNP (60-120 min)47.
Comparisons of diagnostic performance between ANP and BNP support the use of BNP
so most clinical diagnostic tests employ BNP and NT-proBNP as circulating biomarkers
of HF52.
ANP is secreted by the atria of the heart in response to hypertension and wall stress caused
by increased blood volume. BNP and NT-proBNP are also markers of volume load and
wall stress. The use of BNP and NT-proBNP is established as a standard to rule out HF, as
recommended by the Canadian Cardiovascular Society’s Heart Failure Management
Guidelines18. However, comorbidities are confounding variables and must be accounted
for when measuring BNP levels. Circulating BNP is reduced in obese patients53 and
patients with renal failure and HF have elevated plasma NT-proBNP48. Both compounds
are elevated with age and differ based on sex54,55. A study in 558 patients with chronic HF
found that BNP levels varied with age and renal function56. Notably, they also observed
large variations in asymptomatic patients (NYHA class I) with values ranging beyond
clinical cutoffs for more severe diagnosis. One-fifth of patients studied with symptomatic
HF (NYHA class II or III) had levels less than the median value observed in asymptomatic
patients. The results suggested that BNP levels in HF could also depend on yet unknown
factors as well as disease severity and genetic polymorphisms56. With such variability, it
has been postulated that using circulating BNP levels may be unsuitable in HF
management47.
Cardiac troponins (cTns) T and I are leading candidates in the search for novel HF
biomarkers57. They are well established as biomarkers for myocardial injury and are
historically used to diagnose myocardial infarction. cTns are markers of remodeling
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associated with myocyte injury and death and have shown utility in diagnosis and prognosis
in HF58. Serial measurements are used as predictors of cardiac remodeling. Unfortunately,
there are several conditions were cardiac troponin levels are elevated including
hypertension, myocarditis, cardiac amyloidosis, and hypertrophic cardiomyopathy59.
Moreover, remodeling occurs in the later stages of HF which does not provide adequate
appraisal of HF development.
Although simple blood tests can be used to detect the circulating biomarkers discussed,
many of these compounds are not specific to cardiac tissue and are produced by several
tissues in response to injury or when heart tissue is dysfunctional. It is also possible that
circulating levels do not reflect cardiac levels. These are significant limitations to current
biomarkers in comparison with tissue-specific cardiac biomarkers. There is a need for
identification and noninvasive detection of cardiac-specific biomarkers for HF.
Furthermore, Jungbauer and colleagues showed that incorporating a tandem of biomarkers,
that indicate different pathological pathways, provides better prognostic indication than a
single biomarker alone60. This suggests that an approach with multiple biomarkers is useful
in guiding HF management. Also, because HF is a complex syndrome with varying
characteristics, a single or limited panel of biomarkers might not be reflective of its
characteristics.
An emerging biomarker that is cardiac-specific and could be added to the established
repertoire is the growth hormone secretagogue receptor and its ligand, ghrelin. We will
further elaborate on the ghrelin/GHSR1a system in the heart as a biomarker for HF.

1.4 Ghrelin and GHSR1a
In the pursuit of discovering biomarkers for HF, there is growing interest in the hormone
ghrelin and its receptor, the growth hormone secretagogue receptor (GHSR1a), and their
connection to HF. There is a growing body of research supporting their use as indicators
of HF.
The peptide hormone ghrelin augments systemic metabolism by stimulating appetite and
regulating food intake61. Plasma ghrelin levels are elevated in a fasted state and decrease
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after a meal62. Ghrelin is produced from cleavage of pro-ghrelin and activated after posttranslational linkage to octanoic acid by ghrelin O-Acyltransferase (GOAT). The active
hormone is 28 amino acids in length and its structure contains an n-octonoylated serine
residue, the third amino acid, which is required for binding and activation of its receptor,
GHSR1a. GHSR1a is a G-protein coupled receptor (GPCR) that is 366 amino acids long
and contains seven transmembrane domains with an extracellular binding region for
ghrelin. Its splice variant, GHSR1b, is a truncated version with 289 amino acids, and lacks
transmembrane domains 6 and 7. Its biological activity is unknown63,64 and it does not bind
ghrelin65.
Kojima and colleagues66 originally isolated ghrelin from rat and human stomachs, but its
production has since been documented in other tissues, including the heart where it is
thought to exert paracrine or autocrine functions. One of the effects of ghrelin binding and
activation of GHSR1a is the release of growth hormone (GH), and some of the positive
downstream effects of ghrelin on the heart are thought to be GH-dependent67. Ghrelin has
been shown to have a cardioprotective effect in vitro by protecting cardiomyocytes from
apoptosis68 and improves ventricular remodeling in rats following MI69. In healthy
volunteers70 and patients with HF71, ghrelin administration reduced TPR (vasodilatory
effect) and lead to an increase in CO, suggesting a potential therapeutic role in HF. Ghrelin
and synthetic GHSR1a agonists like hexarelin have positive effects in cardiac remodeling
in animals and humans72. While binding of ghrelin activates GHSR1a and results in GH
release, GHSR1a mediated actions independent of GH secretion have been documented73.
Notably, local cardiac production of ghrelin and myocardial expression of GHSR1a67,74,75
suggests that there is a ghrelin/GHSR1a system in the heart. A study conducted by BeirasFernandez and colleagues demonstrated that cardiac GHSR1a expression is elevated in
patients with HF51. A separate study by Chen76 et al. found that plasma ghrelin
concentration is lower in patients with HF and plasma levels were related to HF severity,
where high levels in the blood were related to favourable outcomes in HF patients. Ghrelin
levels have also been documented to resolve to normal levels in HF patients post-heart
transplantation78,79.
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While both ghrelin and GHSR1a have been shown to be relevant to cardiac function,
ghrelin is produced by many tissues. As such, measurement of cardiac GHSR1a can be a
powerful cardiac-specific biomarker for diagnosis and monitoring in HF patients.
There have been efforts to image GSHR1a using PET and SPECT. Several of these studies
merely radio-labelled the ghrelin peptide to make it suitable for imaging. The first study to
target GHSR1a used [125I-His9]-Ghrelin80. They examined its binding properties in vitro
using samples from non-diseased human hearts and demonstrated specific and reversible
binding. [125I-His9]-Ghrelin also bound in samples of human vasculature and showed
elevated uptake in atherosclerotic vessels compared to healthy vessels. However, this study
was entirely in vitro and failed to quantify stability, clearance, and metabolism of the
labelled ghrelin probe. While [125I-His9]-Ghrelin shows promise in vitro, there are still
questions about its in vivo properties and potential for use in imaging.
Kozminski and Gniazdowska81 investigated

99m

Tc-labeled ghrelin analogs as SPECT

diagnostic imaging agents for cancer staging. Probe stability, lipophilicity, in vitro binding,
affinity, and in vivo biodistribution in mice were investigated. Their results suggested that
two of their compounds were stable in human serum over 120 min, but they did not show
further time-points or determine a biological half-life. The same two conjugates
demonstrated strong, low nanomolar binding for the receptor (54  4 nM and 45  3 nM).
Their investigation, however, did not evaluate the probes’ in vivo specificities or their
sensitivities for detecting changes to GHSR1a expression. In vivo mouse studies consisted
of biodistributions at 30 and 60 min post-injection with the two most promising tracers.
Unfortunately, both demonstrated relatively low heart uptake (<1.5 %ID/g for both at 30
min and 60 min).
A very recent study was published that investigated possible PET and molecular imaging
probes using ghrelin82, however these probes have yet to see in vivo evaluation as a
potential radioligands for GHSR1a imaging. Moreover, none of the ghrelin-based probes
described so far have been assessed by imaging and, while ghrelin-based tracers generally
show high affinity for the receptor, they are substrates for the same metabolic enzymes as
the natural hormone which impacts their in vivo stability and use as imaging agents.
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Consequently, the ghrelin basis as structure may not be suitable for imaging83. Others have
developed and investigated peptidomimetic and small molecule radiolabeled tracers which
may mitigate this limitation.
Labeled ghrelin and ghrelin analogs are contrasted with those of peptidomimetics in a study
by Chollet and colleagues83 where they assessed the potential of several ghrelin receptor
agonists and inverse agonists using combinations of ghrelin and non-ghrelin mimetics. The
peptides were synthesized and conjugated to the chelator NODAGA which complexes with
68

Ga. The pharmacokinetic profile and metabolic stability of the

68

Ga-NODAGA-

radiotracers were investigated in vivo by µPET imaging in rats. Ghrelin derived agonists
accumulated in the kidneys, were not taken up by many tissues and were metabolized and
cleared quickly. Their most promising candidate was an inverse agonist peptidomimetic
that demonstrated stability in the blood and low blood clearance. Unfortunately, it
displayed high non-specific tissue perfusion and low binding affinity. They suggested that
a radionuclide with longer-half-life than

68

Ga (t1/2 = 68 min) would be useful for longer

imaging studies and to better understand clearance pathways.
Potter et al.84 investigated the ghrelin receptor as a modulator of feeding behaviour using a
small molecule quinazolinone derivative and GHSR1a antagonist called (S)-6-(4fluorophenoxy)-3-((1-[11C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one
([11C]1). They discovered it had relatively high binding affinity in vitro, but it did not
demonstrate high heart uptake in vivo, and instead distributed to the lung and liver with
relatively high non-specific binding.
In light of the promise GHSR1a shows as a target in understanding the molecular
mechanisms of HF, its potential use as a biomarker and therapeutic target, and the lack of
encouraging imaging agents available, we sought to test a novel peptidomimetic PET tracer
for noninvasive imaging of GHSR1a.

1.5 Rationale, Motivation, and Previous Work
While there are established clinical work ups to diagnose, monitor, and treat HF, clinical
imaging modalities like chest radiography, echocardiography and CT largely report
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changes to anatomic structure and pathologic function in the heart, which occur after HF
has developed. Biomarkers can be useful in identifying subclinical changes. However,
current biomarkers are produced by many tissues and are obtained from the circulation.
They provide a systemic measurement of function rather than reporting solely cardiac
changes. Molecular imaging of biomarkers enables researchers and clinicians to gain
insight into the metabolic and molecular changes that characterize the development and
progression of cardiomyopathies prior to gross structural and physiologic abnormalities.
Along with the current assortment of HF biomarkers available, several others are being
actively investigated. A promising candidate is GHSR1a, which binds the peptide hormone
ghrelin. Human myocardial expression of GHSR as assessed by radiolabeled hexarelin was
significantly higher than any other tissue evaluated85, indicating its potential as a novel
cardiac-specific biomarker for noninvasive imaging in HF.
Our group has previously synthesized and evaluated tools for visualizing GHSR1a
expression. We86,87 and others88 have developed fluorescent imaging agents to target
GHSR1a as a biomarker of cardiomyocyte survival. The fluorescent agent is the
fluorescently-tagged and truncated peptide ghrelin(1-19). Our group has since shown in
vivo applications of modified ghrelin analogues for in vivo PET imaging of GHSR1a89. We
have since produced and tested the PET tracer 68Ga-ghrelin(1-19) for targeting GHSR1a in
a mouse model of diabetic cardiomyopathy, where

68

Ga-ghrelin(1-19) demonstrated

correlation between receptor expression and probe uptake90. The current lead compound is
a growth hormone secretagogue (GHS), a class of low molecular weight peptidomimetics
that bind GHSR1a, labelled with the longer-lived isotope
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F (half-life = 110 min) and

contains unnatural amino acids in its structure which protect from degradation by
peptidases in vivo. It has previously been characterized in vitro and has shown strong
GHSR1a binding (IC50 = 69 nm) and activation (EC50 = 1.1 nm).
By moving from a fluorescent agent to a PET imaging agent, we can develop a clinically
translatable probe. Using a peptidomimetic probe over the previously used ghrelin analogs
should result in superior targeting, stability, and pharmacokinetics. We propose that
GHSR1a may be a biomarker for subclinical cardiomyopathy and potentially provide
insight into pathogenesis of the clinical syndrome of HF. In this work, we describe the in
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vivo characterization of our current lead compound, a GHS called [1-Nal4, Lys5(4-[18F]FB)]G-7039, for imaging cardiac GHSR1a as a biomarker for HF.

1.6 Objectives and Hypothesis
The overall objective of our research is to image GHSR1a as a biomarker for HF. In support
of our objective, this study characterizes specificity of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
by PET imaging of GHSR1a in vivo.

1.6.1

Specific Aims

1. Evaluate specificity of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 for GHSR1a in vitro in
GHSR1a expressing cells and non-expressing cells, as well as ex vivo in fasted and
fed normal mice to quantify probe uptake in target and non-target tissues by
biodistribution.
2. Assess specificity of probe in vivo in wildtype (wt) and global receptor-knockout
mice (ghsr-/-). This will be evaluated with in vivo PET imaging of wt and ghsr-/mice and ex vivo investigations of probe biodistribution.
3. Assess the cardiac metabolic profile of fasted and fed normal mice and wt and
ghsr-/- mice using immunofluorescence microscopy of GHSR1a, GLUT4, CD36,
and SERCA2a expression.
4. Quantify [1-Nal4, Lys5(4-[18F]-FB)]G-7039 specificity by relating heart SUV to
GHSR1a expression in wt and ghsr-/- mice.

1.6.1.1

General Hypothesis

We expect that [1-Nal4, Lys5(4-[18F]-FB)]G-7039 will bind GHSR1a in the heart and will
be able to detect changes in GHSR1a with high specificity.

1.6.1.1.1

Specific Hypotheses

1. Ghrelin has greater affinity for GHSR1a than [1-Nal4, Lys5(4-[18F]-FB)]G-7039
and ghrelin levels are expected to be elevated in fasted mice. Therefore, [1-Nal4,
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Lys5(4-[18F]-FB)]G-7039 will exhibit differential cardiac uptake, favouring fed
mice.
2. ghsr-/- mice do not express GHSR1a, so [1-Nal4, Lys5(4-[18F]-FB)]G-7039 will not
be appreciably distributed to the heart and will instead show faster clearance in
ghsr-/- mice.
3. Cardiac metabolic profile of fasted mice will demonstrate preference for lipids over
glucose and fasted ghsr-/- mice will not show a preference for either lipids or
glucose.
4. Heart uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 will be correlated to GHSR1a
expression.
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Chapter 2

2

Materials and Methods

2.1 Tracer Synthesis
The tracer synthesis process was altered during the duration of this project, so described
herein is the final method (Post-SOP), which was automated until step (b) in Scheme 1
(contrasting the initial method [Pre-SOP], which was entirely manual, and is described in
Appendix A).
All the reagents and solvents used for radiosynthesis were purchased from Sigma-Aldrich
unless otherwise stated.
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F-fluoride was produced via the

18

O(p,n) 18F reaction in a GE

PETtrace 880 cyclotron at Lawson Health Research Institute for desired radiotracer
synthesis. GE Tracer Lab FXN was used to prepare and purify [18F]fluorobenzoic acid
([18F]FBA).
As described in Scheme 1, [18F]FBA was prepared on the GE tracer lab FXN. Aqueous
[18F]fluoride solution was trapped on the Sep-Pak AccellTM plus carbonated QMA light
cartridge. 1 mL of acetonitrile/H2O (80/20; v/v) solution containing potassium carbonate
(1 mg) and kryptofix 2.2.2 (7 mg) was used to elute [18F]fluoride into the reaction vial
(Scheme 1ai). The solvent was removed azeotropically in vacuum under the helium flow
at 75°C. [18F]fluoride was dried twice by adding 1 mL of anhydrous acetonitrile
respectively under the above condition. 500 μL of anhydrous DMSO containing 5 mg of
4-(Tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate salt was added into
dried [18F]F- under helium atmosphere (Scheme 1aii). The reaction vial was sealed and
heated at 120°C for 8 min. The reaction mixture was cooled down to 40°C, 1 mL of aqueous
HCl (5 M) was added into reaction vial. The reaction mixture was heated 3 min at 100°C
for hydrolysis of ester and then cooled down to 40°C. 2.5 mL of H2O was added to dilute
the reaction mixture. The product was trapped on Sep-Pak C18 light cartridge (Waters) and
washed with 0.5 mL of H2O. The product was eluted out by 2.5 mL anhydrous acetonitrile
through drying cartridge filled with anhydrous Na2SO4 to get [18F]FBA.

21

The solution of [18F]FBA in 1 mL of acetonitrile was added into the vial containing 20 mg
NHS

(N-Hydroxysuccinimide)

and

50

mg

EDC

(1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide). The reaction was performed at room temperature for
8 min and then additional 50 mg of EDC was added. The solvent was removed in V-10
evaporator after additional 7 min. 1 mL of 36% Acetonitrile/H2O mixture was added into
the reaction vial. The raw product was purified on semipreparative HPLC column. The
solvent was removed on V-10 evaporator to get dried [18F]SFB (radiochemical purity
>99%).
The solution of 1 mg of [1-Nal4]G-7039 in 500 μL acetonitrile and 100 μL H2O was added
into the above [18F]SFB vial and followed by the addition of 5 μL DIPEA (N,NDiisopropylethylamine) (Scheme 1c). The reaction mixture was heated at 85°C for 15 min.
500 μL H2O was added into reaction vial after cooling down to room temperature. The
reaction mixture was purified in semipreparative column to get [1-Nal4, Lys5(4-[18F]FB)]G-7039 (39% yield decay corr.).

Scheme 1. Radiosynthesis of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
Reagents and conditions: (a) (i) 18F-, K2CO3, Krypofix 222, DMSO, 120°C, 8 min, (ii) HCl
(5 M), 100°C, 3 min; (b) NHS, EDC, acetonitrile, RT, 15 min; (c) DIPEA, acetonitrile/h2O,
85°C, 15 min.
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2.2 In Vitro Characterization
Serum stability studies were performed to evaluate [1-Nal4, Lys5(4-[18F]-FB)]G-7039’s
biological half-life and suitable time-frames for PET imaging. For quantitative assessment
of GHSR1a function, cell uptake studies were conducted by applying [1-Nal4, Lys5(4-[18F]FB)]G-7039 to OVCAR8 cells transfected with GHSR1a and cells lacking GHSR1a at
various time-points.

2.2.1

Serum Stability

[1-Nal4, Lys5(4-[18F]-FB)]G-7039 (1 mM final concentration) was incubated in a mixture
of 25% human serum (Sigma-Aldrich, St. Louis, Missouri, United States; Male type AB
cat# H4522) in PBS (phosphate buffered solution, pH 7.4, 450 uL final volume, DMSO
final concentration 0.5%) at 37°C. This concentration of human serum was chosen based
on standard protocols observed in literature and ease of peptide extraction91. At 20, 60,
240, 420, and 1440 min after incubation, aliquots of peptide solution were removed and
mixed with either acidic solution (4% phosphoric acid, pH 1-2) or basic (4% ammonium
hydroxide, pH 11-13) to dissociate peptide interactions with components of human serum.
Peptide was isolated from human serum by column separation on Oasis sorbent 96-well
μElution plates (HLB- amphiphilic resin and MCX-cation exchange resin) and manifold.
The extracted peptide was quantified on an Acquity UHPLC-MS system. Peptide was
quantified by measuring the peak area of a peptide-specific M+n ion peak and averaged
over 3 replicates. Percent abundance of peptide peak area relative to abundance at T0 was
plotted as a function of time. Peptide half-life was calculated by optimized curve fitting
(linear, 2-parameter or 3-parameter exponential decay curve) on SigmaPlot v.12 and
solving for time at 50% peptide peak abundance.

2.2.2

Cellular Uptake

Using synthesized [1-Nal4, Lys5(4-[18F]-FB)]G-7039, the in vitro targeting potential of the
probe for GHSR1a was evaluated. OVCAR8 cells (courtesy of Dr. Trevor Shepherd,
Department of Anatomy and Cell Biology, UWO, to Dr. Leonard Luyt) stably transected
with GHSR1a and non-transfected cells were released from the tissue culture flask by
trypsinization and plated in a 6-well dish at a cell density of 4 x 105 cells/well. The cells
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were incubated overnight at 37°C and 5% CO2 in air in RPMI (Sigma-Aldrich) containing
10% fetal bovine serum (FBS; pH 7.4). After 24 h, RPMI media with 10% FBS was
removed and serum-free RPMI media was added 20 min prior to addition of tracer. [1Nal4, Lys5(4-[18F]-FB)]G-7039 (2.8 MBq/mL) in 100% ethanol was added to each well
(final ethanol concentration of ≤ 1%). After 5 min, 20 min, and 60 min incubations with
0.34–8.6 MBq of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 at 37°C and 5% CO2, cells were
washed twice with PBS (pH 7.4),and detached from the plate with 0.5M EDTA (pH 8).
Each time-point was repeated in triplicate in transfected and non-transfected cells.
Medium and detached cells were transferred to 0.5mL Eppendorf tubes. Radioactivity was
then counted in a high-purity Ge gamma counter (Ortec GWL-190-15S, detection range
12.55-2111 keV). Activity was determined with energy windows ranging 507.18-515.43
keV and 1018.44-1026.68 keV (the energies of
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F are 511 keV and 1022 keV). The

radioactivity was calculated in becquerels (Bq) and decay corrected to the time of
incubation with probe. Probe uptake was calculated as a percentage relative to incubated
dose (%ID).

2.3 Mice
Animal protocols were approved by the Animal Use Subcommittee at Western University
(Western University, London, Ontario, Canada) and animals were treated per ethical
guidelines set by the Canadian Council on Animal Care (CCAC). Documentation of ethics
approval can be found in Appendix C.
For biodistribution studies, C57BL/6 mice were obtained from Charles River Laboratories
(Wilmington, Massachusetts, United States) at 7-9 weeks of age and sacrificed between 818 weeks. ghsr-/- mice were originally generated on a C57BL/6J background strain
(generously supplied by Dr. Alfonso Abizaid, Carleton University, Ottawa, Ontario,
Canada)92. ghsr-/- mice were produced by breeding mice heterozygous for ghsr. Tail
samples were obtained from offspring for genotyping when mice were 14-16 days old.
Samples were genotyped by PCR using reverse and forward primers for ghsr and lacZ,
which was the control for ghsr-/- mice (Appendix D). Three female wt mice were also
obtained from Jackson Laboratories (Bar Harbor, Maine, United States) at 15 weeks of age
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and wt and ghsr-/- mice were sacrificed between 16-23 weeks. All mice were fed a diet of
standard rodent chow and water, and group-housed in a temperature controlled room
(23°C) with a 12 h light-dark cycle with lights-on at 0700h for the study’s duration.

2.4 Biodistribution
In vivo probe uptake was assessed by biodistribution in female C57BL/6 mice (8-18 weeks
of age). Animals were randomly assigned to fasted or fed groups and 1 h, 2 h, or 4 h postinjection sacrifice time-points (n≥6 for each time-point in each group). Food was removed
from fasted mice 4 h prior to injection and throughout biodistribution studies. Fed mice
had access to food ad libitum throughout experiments. Both groups had access to water.
Prior to injecting the probe, animals were anaesthetized under 3% isoflurane in 100%
oxygen at a constant flow rate of 2 L/min using a sealed nose cone. Once anaesthetized,
mice were ventilated with a mixture of 1.5-2% isoflurane in 100% oxygen at 1.5-2 L/min
constant flow rate and kept warm with a heat lamp during tail vein catheter insertion.
Animals were injected with 5.23-26.4 MBq of [1-Nal4, Lys5(4-[18F]-FB)]G-7039. Postinjection, mice were recovered in normal room air and returned to their respective groups.
At the appropriate time-point, mice were sacrificed by cervical dislocation under 5%
isoflurane anaesthetic in 100% oxygen at 2L/min. The heart and other organs of interest
were resected whole, with the exception of bone, sampled from the right tibia, and muscle,
taken from the left quadriceps. Organs were weighed and their radioactivity was counted
in a high-purity Ge gamma counter. The radioactivity in sampled tissues was calculated in
Bq and decay corrected to the time of injection. Probe uptake was calculated as a
percentage relative to the injected dose per gram of tissue (%ID/g).

2.5 µPET and CT Imaging
In vivo probe specificity was evaluated by PET imaging of wt and ghsr-/- mice. Animals
were fasted 4 h prior to injecting the probe and then anaesthetized and ventilated as
described in biodistribution studies.
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2.5.1

µPET

After insertion of a tail vein catheter, 90 min dynamic emission scans were initiated 30s
before wt (n=6) and ghsr-/- (n=6) mice were injected with 5.6-15.9 MBq of probe. Mice
were scanned in an Inveon preclinical PET scanner (Siemens Medical Solutions, Erlangen,
Germany), which provides a 161 mm (diameter) x 127 mm (axial) field of view, a fullwidth half-maximum (FWHM) between 1.4 mm and 1.8 mm, and reconstructed resolution
of 1.65 mm3.93 Image acquisition and reconstruction were conducted using scanner
supplied software (Inveon Acquisition Workspace and microQ Viewer, respectively).
Once PET scanning concluded, the mouse and bed were removed together and transported
to the CT scanner, taking care to maintain the mouse’s position on the bed and the same
anaesthetic conditions during the transfer. These precautions ensured minimal movement
of the mouse between PET and CT scans.

2.5.2

Computed Tomography

Computed Tomography (CT) scans were acquired on a clinical Revolution CT scanner
(General Electric, Schenectady New York, United States). Mice were anaesthetized as in
the dynamic PET scan. The CT acquisitions were performed with settings of 4.0 cm FOV,
120 kV, 300 mA, and 192 slices of 0.625 mm thickness. Total scan time was 1.0 s. Scans
provided anatomical reference for PET scans.
Following CT scans, mice were sacrificed and biodistributions were performed as
described in Section (2.4). Time of sacrifice post-injection varied with several factors
including transport from PET to CT machines. Mice were sacrificed between 2-2.5 h after
injection with the probe.

2.5.3

PET Image Reconstruction and Analysis

Dynamic PET imaging data was binned into 13 imaging frames of 12 frames x 5 min and
1 frame x 30 min (2.5x zoom and Nyquist filter applied). Data was decay corrected to the
time of injection and images were corrected for dead time, random and scatter coincidences
prior to reconstruction using the three iterations of ordered subsets-expectation
maximization algorithm (OSEM3D; 18 iterations of 16 subsets) with scanner supplied
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software (microQ viewer) and analysis in 3D Slicer (v. 4.6.2). Standardized uptake values
were calculated using Equation 1 below from volumes of interest (VOIs) drawn around
volumes corresponding to the heart, lungs, and abdomen on PET images overlaid with CT
images. Heart uptake was corrected for spillover activity from the lungs using Equation 2,
where RC is the recovery coefficient (which we have set equal to 0.93 for the mouse heart,
based on values for a phantom of similar size94).
Equation 1. SUV calculation
𝑆𝑈𝑉 = 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑉𝑂𝐼 [𝐵𝑞/𝑐𝑐]×

𝑚𝑜𝑢𝑠𝑒 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 [𝑔]
𝑡𝑜𝑡𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑[𝐵𝑞]

Equation 2. Heart SUV correction
𝑆𝑈𝑉𝐻𝑒𝑎𝑟𝑡 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =

𝑆𝑈𝑉𝐻𝑒𝑎𝑟𝑡 − (1 − 𝑅𝐶)×𝑆𝑈𝑉𝐿𝑢𝑛𝑔
𝑅𝐶

2.6 ELISA
During biodistribution and proceeding imaging studies, 75 µL of whole blood was
collected into heparinized syringes by cardiac puncture. Samples were dispensed into tubes
containing 25 µL Complete, Mini protease inhibitors (Sigma-Aldrich) in PBS, gently
mixed, and stored and transported on ice. Tubes were centrifuged at 3000 rpm for 10 min
at 4°C, then 50 µL aliquots of supernatant plasma were collected and stored at -80°C until
assayed.
Plasma samples were thawed at room temperature, 40 µL was collected, and ELISA was
conducted (LUMINEX 200 multiplex assay, Luminex Corporation, Austin, Texas, United
States). Blood plasma samples were analyzed for concentrations of ghrelin, glucagon,
glucagon-like peptide-1 (GLP-1), and insulin and results were given in pg/mL.

2.7 Immunofluorescence Microscopy of Heart and Lungs
Immunofluorescence microscopy was used to evaluate expression of GHSR1a in the heart
and lungs, as well as to assess markers of metabolism and contractility in heart samples.
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2.7.1

Hearts

After counting radioactivity, excised hearts from fasted and fed mice sacrificed at 1 h postinjection and wt and ghsr-/- mice were fixed in 4% paraformaldehyde (PFA; Electron
Microscopy Sciences, Hatfield, Pennsylvania, United States) buffered with PBS (pH 7.07.4). Hearts were then perfused in increasingly higher concentrations of sucrose solution
(5%, 10%, 15%, each for at least 30 min, then 30% for 24 h), dried, and embedded in frozen
tissue embedding medium (OCT; ThermoFisher Scientific, Waltham, Massachusetts,
United States) and then frozen at -80°C. Serial sections were cut (Leica CM 1850 cryostat)
at 7µm thickness and four sections were selected for immunohistochemistry per subject.
Tissue sections were thawed in PBS and incubated in blocking buffer (1% Bovine Serum
Albumin [BSA] and 10% donkey or goat serum in PBS) for 30 min at room temperature.
Serial sections were stained with primary polyclonal antibodies as described in Table 2 for
1 h at room temperature. GHSR1a was stained for using a fluorescent Cy5-ghrelin probe
(1:100) we have previously characterized in murine cardiac tissue86. Secondary donkey
anti-goat antibodies conjugated to fluorophore Alexa Fluor 488 (1:500, Life Technologies,
Carlsbad, California, United States) and secondary donkey anti-rabbit antibody conjugated
to fluorophore Alexa Fluor 594 (1:500, Invitrogen, Carlsbad, California, United States) for
visualization of ghrelin, SERCA2a, CD36, and GLUT4 were applied for 2 h at room
temperature. Primary and secondary Antibodies and Cy5-ghrelin were diluted in blocking
buffer. Coverslips were then mounted with ProLong Gold liquid mountant containing
DAPI nuclear stain (ThermoFisher Scientific, Waltham, Massachusetts, United States).
Tissue sections were stored overnight at 4°C and coverslips were sealed the next day.

28

Table 2. Primary antibodies used for immunofluorescence microscopy.
Antigen
Ghrelin

Catalog #
sc-10368

Dilution
1:100

Host
Goat

RRID#
AB_2232479

Source Company
Santa Cruz
Biotechnology

Serca2A

ab3625

1:300

Rabbit

AB_303961

Abcam

CD36

nb400-144

1:200

Rabbit

AB_10003498

Novus Biologicals

GLUT4

sc-1608

1:100

Goat

AB_445037

Santa Cruz
Biotechnology

2.7.2

Lungs

Three wt and three ghsr-/- mice (29 weeks of age) were selected for microscopy to quantify
GHSR expression in pulmonary tissue. Mice were sacrificed with an intraperitoneal
injection of sodium pentobarbital (110mg/mL, Lundbeck, Valby, Denmark). A midline
incision was made in the abdomen and through the diaphragm and ribcage. The vena cava
was injected with 50µL of heparin (1000IU/mL) and a cannula was inserted and secured
in the right pulmonary artery. The vasculature was infused with 1mL saline through a small
incision in the left ventricle. The lungs, heart, and trachea were removed intact. Lungs were
suspended and filled with 4% PFA fixative to a pressure of 15 cm H2O. An airtight knot
was drawn around the trachea and lungs were immersed in 4% PFA for 24 h95. Lungs were
resuspended in PBS post-fixation, changing solution every 12 h for 48h. Finally, the lungs
were immersed in 70% ethanol and stored at 4°C until further processing.
Lungs were placed coronally in cassettes for paraffin embedding. Lungs were embedded
in paraffin wax and sectioned sequentially from anterior to posterior. Three sections per
subject were selected for H&E staining approximately 14 µm apart and three adjacent
sections were stained for GHSR1a with Cy5-ghrelin.
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2.7.3

Microscopy Image Acquisition and Quantification

Five random fields of view per cardiac and pulmonary tissue section were acquired at 20x
magnification (for immunofluorescence microscopy: Nikon NIS Elements v. BR 4.50.00,
Shinagawa, Tokyo, Japan; and for histology: Northern Eclipse v5.15.4.0, EMPIX Imaging,
Mississauga, Ontario, Canada). GHSR1a was imaged with a Cy5 filter with 100ms
exposure. Ghrelin and GLUT4 were imaged with FITC filter with 800ms exposure. CD36
and SERCA2a were imaged with TRITC filter with 500ms exposure.
Images were imported for analysis into FIJI v. 1.49v, a distribution of ImageJ (National
Institutes of Health, Bethesda, Maryland, United States). Fluorescence was quantified
using a custom FIJI script that measures fluorescent intensity, which represents protein
levels, across an image and returns the raw integrated density, as done previously86,96.

2.8 Statistical Analyses
Statistical analyses were conducted and graphs were plotted using GraphPad Prism v. 7.00
(San Diego, California, United States). Differences in cell uptake were analyzed using twoway repeated measures ANOVA and Bonferroni post-hoc test. For biodistributions, within
group differences between organs sampled and between time-points in fasted, fed, wt, and
ghsr-/- mice were determined using two-way ANOVA followed by Tukey’s multiple
comparisons test. Between group differences in fasted and fed mice in matching organs at
the same time-point were analyzed by two-way ANOVA and Bonferroni’s multiple
comparisons test. Two-way ANOVA was also used to assess differences in plasma proteins
evaluated by ELISA. Data from dynamic PET SUVs was evaluated using two-way
repeated measures ANOVA followed by Bonferroni’s multiple comparison’s test for
between group differences and Tukey’s multiple comparison’s test for within groups
differences. Static PET SUVs and between group comparisons of plasma protein levels
from ELISA measurements were evaluated using unpaired two-tailed Student’s t-test. For
immunofluorescence microscopy images, differences in mean fluorescence between fasted
and fed mice and between wt and ghsr-/- mice were determined by two-way ANOVA and
Bonferroni’s multiple comparisons test. Grubb’s test was used to address outliers in plasma
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protein and fluorescence data. Outliers were removed from final analysis. For correlations,
linear regression analysis was used. Significance was set at p<0.05 for all statistical tests.
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Chapter 3

3

Results

3.1 Physicochemical Characteristics of [1-Nal4, Lys5(4-[18F]FB)]G-7039
Note: [1-Nal4, Lys5(4-[18F]-FB)]G-7039 was synthesized, radiolabeled, and HPLC
analyzed pre-SOP by Tyler Lalonde (Appendix A) and post-SOP by Lihai Yu (described
below).
The chemical structure of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 is shown in Figure 1. Receptor
binding assays in human embryonic kidney (HEK293) cells stably transfected with
GHSR1a were previously conducted to assess the binding affinity of [1-Nal4, Lys5(4-[18F]FB)]G-703997. The binding affinity was evaluated by the half-maximal inhibitory
concentration and was found to be IC50

=

69 nM. Calcium flux assays were used to

determine the receptor activation as determined by the half-maximal effective
concentration (EC50), which was calculated as EC50 = 1.1 nm. The same properties were
assessed in human ghrelin and determined to be IC50 = 7.63 nm and EC50 = 1.6 nm97. The
partition coefficient (logP) was calculated using ACD/LogP software to assess [1-Nal4,
Lys5(4-[18F]-FB)]G-7039 lipophilicity and was found to be 8.76  0.88.
Using the Post-SOP synthesis method yielded [1-Nal4, Lys5(4-[18F]-FB)]G-7039 with a
decay-corrected radiochemical yield of 39%, radiochemical purity ≥ 99% and a molar
activity of > 4.7 GBq/μmol after 81 min.
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Figure 1. Chemical structure of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
[1-Nal4, Lys5(4-[18F]-FB)]G-7039’s in vitro binding affinity is IC50 = 69 nM and its in vitro
potency is EC50 = 1.1 nm. The partition coefficient was calculated as logP = 8.76  0.88.
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3.1.1

Serum Stability of Unlabeled Probe

Serum stability was analyzed in 25% human serum in PBS at 37°C to determine the in vitro
stability of the unlabeled compound [1-Nal4, Lys5(4-FB)]G-7039. Peptide half-life was
calculated by optimized curve fitting. An exponential decay curve was generated (Figure
2) and described by Equation 3 below, where “y” represents the percentage of remaining
peptide and “t” represents the time in minutes.
Equation 3. [1-Nal4, Lys5(4-FB)]G-7039 biological decay
𝑦 = 99.8𝑒 −0.0009𝑡 − 1.7
Based on Equation 3, the half-life of [1-Nal4, Lys5(4-FB)]G-7039 in 25% human serum is
730.8 min (12.2 h). By extrapolation, the physical half-life in 100% serum would be 182.7
min (3.05 h).

3.1.2

Cellular Uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039

Uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 in OVCAR8 cells stably transfected with
GHSR1a was compared to wt cells lacking the receptor. Two-way repeated measures
analysis of variance determined that there were differences with respect to time point
(p<0.01) and cell type (p<0.05). As shown in Figure 3, both groups demonstrated a timedependent uptake pattern. Bonferroni post-hoc analysis did not return differences between
wt and transfected cells at any of the time-points examined.

% P e p t id e R e la t iv e t o T 0
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Figure 2. In Vitro serum stability of [1-Nal4, Lys5(4-FB)]G-7039
Stability of [1-Nal4, Lys5(4-FB)]G-7039 was assessed in vitro by incubating 1 mM of
peptide in human serum at 20, 60, 240, 420, and 1440 min. Data points represent the
average of three replicates  SEM and are presented as a percentage of peptide abundance
relative to abundance at T0.
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Figure 3. Cell uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
The target cell uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 in OVCAR8 cells stably
transfected with GHSR1a (blue) and wt OVCAR8 cells (red). Uptake was time-dependent
in both cell types with no differences in uptake between them. Each value is presented as
mean  SEM (n=3).
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3.2 Ex Vivo Biodistribution in Fasted and Fed Mice
Ex vivo biodistributions were conducted in fasted and fed female C57BL/6 mice to
determine the time-point and conditions where uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
was highest in the heart, thus providing support for a suitable imaging protocol (Figures 4
& 16). Uptake values were calculated as a percentage of the decay corrected total injected
dose and normalized to each tissue’s weight (%ID/g). Because the first step in the synthesis
protocol for [1-Nal4, Lys5(4-[18F]-FB)]G-7039 was changed from manual to automated
(pre-/post-SOP), we evaluated biodistributions using both methods. The Post-SOP results
are shown below. Pre-SOP results can be found in Appendix B.

3.2.1

Results Post-SOP

[1-Nal4, Lys5(4-[18F]-FB)]G-7039 exhibited similar uptake profiles in fasted and fed mice
(Figure 4). Negligible heart uptake was observed in both groups. The probe distributed
primarily to the lung, spleen, liver, and urine. Differences between fed and fasted mice at
the same time-point were not significant except in urine at 2 h (p<0.05). Within groups,
differences in uptake were observed between time-points in the same organ and between
organs at the same time-point.
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Figure 4. Biodistribution profile of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 using PostSOP probe synthesis
Fasted (A) and fed (B) female C57BL/6 mice injected with [1-Nal4, Lys5(4-[18F]-FB)]G-7039 were
sacrificed 1 h, 2 h, and 4 h post-injection. Urine samples are n=4, 6, 5 in (A) and n=2, 4, 5 in (B)
at 1 h, 2 h, and 4 h respectively. Values are mean injected dose per gram tissue (%ID/g)  SEM.
As shown in (A): *p<0.05 in liver at 2 h vs all tissues (except spleen), ****p<0.0001 in urine at 2
h vs all other tissues, # p<0.05 in liver at 2 h vs 4 h, ####p<0.0001 in urine at 1 h vs 2 h and 2 h vs
4 h, and +p<0.05 in fasted urine vs fed urine. As shown in (B): *p<0.05 in liver at 1 h vs all tissues
(except spleen, tail, and urine), and in urine at 1 h vs all tissues (except liver), **p<0.01 in urine at
2 h vs all tissues, and ##p<0.01 in urine at1 h vs 4 h and ####p<0.0001 at 2 h vs 4 h.
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3.3 Plasma Concentrations of Ghrelin, Glucagon, GLP-1,
and Insulin in Fasted and Fed Mice
To establish whether circulating ghrelin affected binding, plasma levels of ghrelin, along
with other proteins known to be influenced by nutritional state (glucagon, glucagon-like
peptide-1 [GLP-1], and insulin) were assessed by ELISA using blood samples from fasted
and fed mice sacrificed 1 h, 2 h, and 4 h post-injection (Figure 5). Concentrations are given
in pg/mL. Plasma ghrelin levels were independent of time point or nutritional state as
evaluated by analysis of variance. No differences between fasted and fed were observed in
other time-point-matched plasma protein concentrations.

3.4 Heart Immunofluorescence in Fasted and Fed Mice
Sections of hearts excised from fasted (n=8) and fed (n=6) mice sacrificed 1 h postinjection were imaged using immunofluorescence microscopy to evaluate expression of
cardiac GHSR1a and markers of cardiac contractility and metabolism, ghrelin, GLUT4,
SERCA2a, and CD36. Two-way analysis of variance returned significant differences with
respect to marker and nutritional state. As shown in Figure 6, post-hoc Bonferroni analysis
revealed significantly lower cardiac ghrelin (p<0.05) levels and cardiac GLUT4 (p<0.01)
expression in fasted mice compared to fed mice. There were no differences observed in the
other markers.
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Figure 5. Plasma concentration of ghrelin, GLP-1, glucagon, and insulin in fasted and
fed mice
Blood plasma concentrations of (A) ghrelin, (B) glucagon-like peptide-1 (GLP-1), (C)
glucagon, and (D) insulin in fasted and fed mice sacrificed 1 h, 2 h, and 4 h post-injection
of [1-Nal4, Lys5(4-[18F]-FB)]G-7039. Values are shown as mean concentration in pg/mL 
SEM.
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Figure 6. Metabolic profiles of heart samples from fasted and fed mice
Cardiac protein levels of metabolic markers (represented by fluorescent intensity) between
fasted (n=8) and fed (n=6) mice sacrificed 1 h post-injection as assessed by
immunofluorescence microscopy. Values are given in raw integrated density (arbitrary
units) of fluorescence. The middle line represents the mean value and the bars indicate
SEM. *p < 0.05, **p < 0.01.
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3.5 In Vivo µPET-CT Imaging
To validate [1-Nal4, Lys5(4-[18F]-FB)]G-7039 specificity for GHSR1a in vivo, wildtype
C57BL/6J and global receptor knockout (ghsr-/-) mice were imaged in list-mode for 60 min
followed by a 30 min static scan. PET images indicated that the regions with greatest signal
intensity corresponded to the lungs and abdomen (Figure 7), but images revealed no
appreciable signal in the heart, aside from the 5 min frame. The signal appeared to decrease
in the lungs in a time dependent manner as it increased in the abdomen.

3.5.1

Time-Activity Curves in wt and ghsr-/- Mice

SUVs were calculated from VOIs assigned to the heart and regions with greatest signal,
corresponding to the lungs and abdomen. Heart uptake as assessed by dynamic (Figure 9)
and static (Figure 10) PET was not different between wt and ghsr-/- mice. Of note, static
SUVs in the heart were significantly correlated (p<0.0001, r = 0.91) with lung SUVs
(Figure 8), indicating that VOIs drawn around the heart were detecting signal from the
lungs. Heart SUVs were corrected for lung spillover using Equation 2 and results are shown
alongside original heart SUVs in Figures 9 and 10. After spillover correction, heart SUVs
were no longer correlated to lung SUVs (r = 0.46).
Analysis of variance determined that differences in mouse model were not significant in
all VOIs investigated for dynamic imaging. Within group differences were found in all
VOIs for time dependent distribution with earlier time points having greatest uptake in
heart and lung and later time points having greater uptake in the abdomen as indicated in
Figure 9.
.
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Figure 7. µPET-CT imaging in wt and ghsr-/- mice
Distribution pattern of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 in wt (top) and ghsr-/- (bottom)
mice recorded with PET. All frames shown are integrated over a 5 min time period, except
the 90 min frame which was integrated over 30 min. Coronal slices through the mouse
body at the section of liver are shown with view from anterior. The arrows indicated regions
where VOIs were drawn.
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Figure 8. Heart SUV pattern is similar to lung SUVs
Correlation between static SUVs in the lung and static SUVs in the heart before spillover
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(p<0.0001). After spillover correction (B), there is no correlation.
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Figure 9. Time-activity curves for [1-Nal4, Lys5(4-[18F]-FB)]G-7039 uptake in wt and
ghsr-/- mice
Heart (A), spill-over corrected heart (B), lung (C), and abdomen (D) uptake of [1-Nal4,
Lys5(4-[18F]-FB)]G-7039. TACs are expressed as SUVs and values are means  SEM (n=6
for wt and n=6 for ghsr-/-). *in wt and #in KO. As shown in (A) and (B): *p<0.05 and
#p<0.05 at 5 min and 10 min vs all time-points (except 15 min). As shown in (C): *p<0.05
and ##p<0.01 at 5 min vs all time-points. As shown in (D): **p<0.01 and ####p<0.0001
at 5 min vs all time-points.
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3.5.2

Static PET in wt and ghsr-./- Mice

To determine if [1-Nal4, Lys5(4-[18F]-FB)]G-7039 PET could detect changes in GHSR1a
expression, static images were acquired over 30 min, at 1 h after probe injection in both wt
(n=6) and ghsr-/- (n=6) mice. The heart was not visualized (Figure 7, 90 min). Probe uptake
was mainly in the lungs and abdomen. The SUVs (mean  SEM) calculated in the heart
(0.69  0.20 vs 0.34  0.12 in wt vs ghsr-/-, respectively; corrected: 0.44  0.19 vs 0.17 
0.06), lungs (5.90  1.96 vs 2.62  1.10), and abdomen (2.44  0.29 vs 2.93  0.31) were
not significantly different between groups in any VOI.

3.5.3

Ex Vivo Biodistributions in wt and ghsr-/- Mice

Following imaging studies, wt (n=3) and ghsr-/- (n=3) mice were euthanized and
biodistribution was performed (Figure 11). Again, negligible heart uptake was observed
and uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 was highest in the lungs of wt mice
(p<0.0001) compared to ghsr-/- mice. In wt mice, the lung also had the highest uptake
compared to all other tissues (p<0.0001).
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3.5.4

Heart Immunofluorescence in wt and ghsr-/- Mice

As in fasted and fed mice, hearts from wt (n=6) and ghsr-/- (n=6) mice sacrificed proceeding
PET-CT imaging studies were embedded, sectioned, and stained for GHSR1a, ghrelin,
GLUT4, SERCA2a, and CD36, and imaged using immunofluorescence microscopy.
GHSR1a expression was significantly less in ghsr-/- mice (p<0.001). Differences were not
observed between wt and ghsr-/- mice in any other markers stained for (Figure 12). Notably,
some GHSR1a fluorescence was detected in the hearts from ghsr-/- mice.
Cardiac ghrelin expression and corrected heart SUVs were plotted as a function of cardiac
GHSR1a expression to assess relationship between cardiac ghrelin and its receptor as well
as probe sensitivity for differential GHSR1a expression (Figure 13). To relate systemic and
cardiac ghrelin levels, plasma ghrelin concentration was plotted against cardiac ghrelin and
the relationship between heart SUV and circulating ghrelin was plotted (Figure 13C and
13D). No convincing correlations were observed between cardiac ghrelin expression and
cardiac GHSR1a expression (r = 0.43), heart SUV and GHSR1a expression (r = 0.47) or
plasma ghrelin (r = -0.16), or plasma and cardiac ghrelin (r = -0.23).

3.6 Lung Immunofluorescence in wt and ghsr-/- Mice
Imaging and biodistribution studies revealed significant [1-Nal4, Lys5(4-[18F]-FB)]G-7039
uptake in the lungs, so we sought to evaluate GHSR1a expression and qualitatively
visualize receptor distribution in lung tissue. Lungs from wt (n=3) and ghsr-/- (n=3) mice
were stained to visualize nuclei by H&E and for GHSR1a expression on adjacent sections.
Fluorescence imaging showed expression of GHSR1a in the lungs of both groups (Figure
14A), but no differences in GHSR1a levels were found (Figure 14B).
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Figure 12. Metabolic profiles of heart samples from wt and ghsr-/- mice
Cardiac protein levels of metabolic markers (represented by fluorescent intensity) between
wt (n≥5) and ghsr-/- (n≥5) mice sacrificed post-PET-CT imaging as assessed by
immunofluorescence microscopy. Values are given in raw integrated density (arbitrary
units) of fluorescence. The middle line represents the mean value and the error bars indicate
SEM. *p<0.001.
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3.6.1.1

GHSR1a Expression and Plasma Ghrelin Concentrations
Compared to Heart SUV
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Figure 13. Correlations of cardiac ghrelin expression, heart SUV, and plasma ghrelin
with cardiac GHSR1a expression
Cardiac ghrelin expression (A) and static SUVs from VOIs assigned to heart in wt (n=5)
and ghsr-/- (n=6) mice (B) plotted as a function of GHSR1a expression. (C) plasma ghrelin
concentration as a function of cardiac ghrelin expression and (D) heart SUV correlation
with plasma ghrelin. Each point represents a value from a single mouse.
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Chapter 4

4

Discussion

HF is a progressive disease and a major cause of morbidity and mortality in patients
suffering from it. It is resource intensive and requires significant economic investment.
Investigations into understanding the fundamental biochemical pathways underlying HF
etiology and progression have resulted in development of targeted pharmacologic and
surgical interventions, in the hopes of mitigating the effects of HF. Laboratory tests are
helpful in identifying signs of end-stage organ dysfunction secondary to the late stages of
HF in the liver or kidneys by examining electrolyte imbalances or neurohormonal
activation. However, these tests measure circulating biomarkers that are not localized to
the heart and are expressed by other tissues. As well, current clinical imaging is useful for
defining heart size, shape, and function to some extent, but most clinical imaging targets
gross changes to structure and function which occur late in the development of HF. Of the
available clinical imaging modalities, PET can elucidate biochemical information
regarding development and evolution of pathology. This study characterized a PET tracer
designed to target a biomarker endogenous to heart tissue.
The expression of cardiac GHSR1a is elevated in patients with HF, so we characterized the
peptidomimetic GHSR1a ligand [1-Nal4, Lys5(4-[18F]-FB)]G-7039 for PET imaging of
cardiac GHSR1a. We hypothesized that [1-Nal4, Lys5(4-[18F]-FB)]G-7039 would bind
GHSR1a with high specificity. Briefly, the objectives of this study were to 1) evaluate [1Nal4, Lys5(4-[18F]-FB)]G-7039 binding specificity and distribution in vitro and in healthy
mice, 2) establish [1-Nal4, Lys5(4-[18F]-FB)]G-7039 specificity for GHSR1a in vivo using
wt and ghsr-/- mice, 3) establish a metabolic profile in the hearts of fasted and fed C57BL/6
mice and wt and ghsr-/- mice, and 4) quantify specificity by relating cardiac receptor
expression and [1-Nal4, Lys5(4-[18F]-FB)]G-7039 uptake.

4.1 Physicochemical properties of [1-Nal4, Lys5(4-[18F]FB)]G-7039
The in vitro binding, activation, and hydrophobicity of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
have been previously evaluated97. [1-Nal4, Lys5(4-[18F]-FB)]G-7039 displayed nanomolar

53

binding affinity (IC50 = 69 nM) in previous work using HEK293/ghrelin receptor cells,
which was within an order of magnitude of native human ghrelin (IC50 = 7.63 nM). It also
had strong in vitro potency (EC50 = 1.1 nM), demonstrating that it is a potent ghrelin
receptor agonist, whereas endogenous human ghrelin is also a strong agonist (EC50 = 1.6
nM). This is important for obtaining signal from the target tissue as GHSR1a is internalized
in response to agonist binding to protect from overstimulation. The ability to internalize
with the receptor is reasoned to make radiolabeled agonists better for persistent signal and
accumulating in tissues of interest, thus improving contrast and in vivo visualization. An
agonist tracer was useful for this work because receptor-ligand internalization is less likely
for antagonists. GHSR1a antagonists have been characterized as imaging agents, but
demonstrated non-specific uptake and retention only in clearance tissues84. However, the
properties of antagonists and inverse agonists allow their use for mapping of receptor
expression98.
At the outset of this study, we experienced difficulties with consistent tracer synthesis,
variable yield, and low molar activity. In an effort to address these problems, the method
for [1-Nal4, Lys5(4-[18F]-FB)]G-7039 generation was altered so that the first step in
synthesis was automated. Using the Post-SOP method, radiochemical purity marginally
improved from >98% to >99%. Decay corrected yield was nearly equivalent, but more
consistent (29-63% Pre-SOP, averaging 52%, to 39% Post SOP). Importantly, there were
dramatic improvements to synthesis time (from 140 min to 81 min), thus improving the
amount of initial activity for studies, and molar activity (116 MBq/μmol to > 4.7
GBq/μmol).
The partition coefficient (logP) is a measure of a compound’s hydrophobicity (by
comparing its distribution in octanol and water). Favourable values for drugs and imaging
agents are in the range of 1-399. A higher logP often results in non-specific binding and, if
the logP value is too high, the imaging agent’s solubility is severely reduced and the probe
is quickly eliminated in vivo100. Therefore, an appropriate logP value is crucial for in vivo
imaging. [1-Nal4, Lys5(4-[18F]-FB)]G-7039 has a logP of 8.76  0.88 suggesting a
challenge for in vivo imaging. However, others have noted that the logP is not necessarily
a predictor of in vivo behavior101 and it is not always easy to predict non-specific binding
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in vivo26. Moreover, [1-Nal4, Lys5(4-[18F]-FB)]G-7039 was the lead compound developed
by our group to target GHSR1a, exhibiting promising binding properties and potency
compared to the next leading compound97, so further in vitro and in vivo characterization
of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 was performed.

4.2 Stability and Cellular Uptake
The biological half-life of [1-Nal4, Lys5(4-FB)]G-7039 was tested in human serum to
assess its stability and help in establishing a time-frame for imaging. Its physical half-life
is 3.05 h. Imaging experiments and biodistributions at 1 h and 2 h were well within one
half-life, and 4 h biodistributions were within two half-lives. Native ghrelin has been
reported to have an in vitro half-life of 4 h in human serum and 30 min in rat serum102.
Others have reported an in vivo half-life of less than 1 h103 and 10 min70. The greater
biological half-life observed for [1-Nal4, Lys5(4-FB)]G-7039 compared to ghrelin may be
explained by the presence of unnatural and D-amino acids its sequence that protect it from
degradation by peptidases in vivo. Moreover, some ghrelin analog tracers exhibit biological
half-lives of less than 5 min83, while others are stable at 120 min81. Thus, [1-Nal4, Lys5(4FB)]G-7039 is a relatively stable compound. Notably, in vitro serum stability was tested,
which does not account for metabolism in the liver and other tissues.
The specificity of [1-Nal4, Lys5(4-FB)]G-7039 was examined by cellular uptake in both
GHSR1a-expressing OVCAR8 cells and in wildtype cells not expressing the receptor. The
probe had a similar uptake pattern in both groups of cells, where uptake was timedependent and independent of receptor expression. This could be due to non-specific
binding and internalization due to the probe’s highly lipophilic character allowing it to
cross plasma membranes, unlike ghrelin which does not freely cross cell membranes104. It
should be noted that the lipophilic character of the probe made administration especially
difficult so relatively high quantities were added to cells and this may have contributed to
cell uptake by saturation kinetics.
In vitro cell uptake studies have the advantage of comparing uptake with respect to ability
to accumulate in cells purely as a function of receptor presence and in vitro stability in
stationary serum can assess metabolism directly related to circulating components. In
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contrast to in vitro studies, in vivo studies can account for many other factors that affect
PET probe uptake, including biodistribution across tissues, metabolism in peripheral
organs and whole blood, and elimination. In vivo studies provide information on tissue
accumulation and time to elimination. Differences in probe behaviour between in vitro and
in vivo are common26, so it is prudent to also evaluate in animal models to obtain a more
complete pharmacologic profile. In vivo target specificity for GHSR1a was evaluated by
conducting biodistribution studies in female C57BL/6 mice.

4.3 Probe Specificity and Effects of Nutritional State on
Binding
Specific aim (1) was intended to address [1-Nal4, Lys5(4-[18F]-FB)]G-7039 specificity in
vivo. This was investigated by conducting ex vivo biodistributions in female C57BL/6
mice. Our group has previously documented higher expression of GHSR1a in the C57BL/6
mouse heart compared to several other tissues87, so this was an appropriate model for
imaging cardiac GHSR1a.
Ghrelin has a higher binding affinity for GHSR1a than [1-Nal4, Lys5(4-[18F]-FB)]G703997, and its secretion is predominantly dictated by nutritional state such that circulating
ghrelin levels are greater when fasted compared to when fed62. In order to ascertain the
best conditions for imaging, we sought to evaluate if fasting affected probe binding in vivo
and to determine the optimal time-point post-injection for imaging.
The biodistribution profile of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 using the Post-SOP
synthesis method was similar in both fasted and fed mice. Primarily, minimal heart uptake
was observed in both groups at all time-points. Instead, the tissues that displayed high
uptake were the lungs, spleen, tail, liver, intestines, and kidneys. High activity was
observed in the urine, even within the first hour, indicating fast clearance. Lipophilic
tracers are commonly transported through the circulation by binding plasma proteins83;
however, fast clearance may explain why tracer distribution to the blood was low. The high
activity in the kidneys and liver indicates sites of excretion and metabolism, respectively.
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Using the Pre-SOP synthesis method, blood concentration of [1-Nal4, Lys5(4-[18F]-FB)]G7039 was stable over time. [1-Nal4, Lys5(4-[18F]-FB)]G-7039 distributed to the heart, and
its uptake appeared to stay consistently elevated across the time-points examined. Human
studies investigating GHSR expression in various tissues found GHSR1b mRNA is highly
expressed (greater than GHSR1a) in the myocardium, but it is unlikely that [1-Nal4, Lys5(4[18F]-FB)]G-7039 is binding GHSR1b because GHSR1b does not bind or respond to
ghrelin or GHSs63. Uptake at 1 h was noticeably higher for nearly all tissues, indicating
that the probe is being eliminated. Non-specific perfusion in all tissues with a slow blood
clearance even after 1 h suggests the probe is being bound by plasma proteins 83. Aside
from uptake in the first hour, liver uptake increased with time from 4 h to 6 h and steadily
washed out of kidneys, lungs, and spleen. This suggests hepatobiliary metabolism and
excretion as the primary clearance pathway.
The presence of impurities can explain divergent biodistribution using the two synthesis
methods. The final product is the same in both cases, so its stability remains unchanged,
however lower bone uptake using the Post-SOP synthesis (<1% compared to ~1-1.5%)
supports the idea that reactants like [18F]FBA and [18F]SFB may have been present in the
final product. Furthermore, lower molar activity using the Pre-SOP method indicates the
presence of unlabeled product, which likely exhibits the same distribution pattern as the
final product using the Post-SOP method, thereby displacing [1-Nal4, Lys5(4-[18F]-FB)]G7039 by binding the same sites without returning measurable signal. Interestingly, using
the Post-SOP synthesis method, the probe did not show high uptake in the brain, which is
known to express high amounts of GHSR1a105. Even though [1-Nal4, Lys5(4-[18F]-FB)]G7039 is lipophilic, it is likely that the concentration gradient from blood to brain was too
low to facilitate transport in the case of Post-SOP synthesis. Meanwhile, brain uptake was
reasonably elevated using the Pre-SOP synthesis method where the concentration gradient
was likely high enough to facilitate crossing of the blood brain barrier.
Biodistribution in fasted mice using Pre-SOP synthesis (Appendix B) demonstrated highest
heart uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 in mice sacrificed 1 h and 4 h postinjection. Considering in vitro half-life was less than 4 h, and only one animal was sampled
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for fed uptake using Pre-SOP methods prior to changeover to Post-SOP, fasting mice prior
to imaging and imaging within the first hour after probe injection appeared appropriate.

4.4 Circulating Metabolic Hormones
After a 4 h fast, there were no differences in plasma concentrations of ghrelin, GLP-1,
glucagon, and insulin, which were selected because their circulating concentrations are
dependent of nutritional state. Such a brief fast may not have been long enough to induce
measurable metabolic changes. Others have found that fasting for 24 h resulted in elevated
plasma ghrelin levels in C57BL/6 mice106, so this may be a more appropriate fasting timeperiod. Also, fed mice had access to food ad libitum so there may have been differences in
feeding behaviour in individual mice which potentially lead to variations in ghrelin levels
among fed mice. Distribution of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 the heart may be
unaffected by circulating ghrelin, however no relationship could be discerned because there
were no differences in cardiac probe uptake or plasma ghrelin between fasted and fed mice.

4.5 Time-Activity Curves
Focal uptake was not visualized in the heart after injection of probe, aside from the 5 min
frame, which can be explained as a first-pass effect. Heart and lung TACs displayed a
washout pattern peaking early in the imaging session (5 min for hearts and 10 min for
lungs). Although not different, uptake in ghsr-/- mice tended to washout more quickly in
both cardiac and pulmonary tissue. Meanwhile, [1-Nal4, Lys5(4-[18F]-FB)]G-7039
accumulated in the abdomen in both groups and plateaued after 15 min, with nonsignificantly greater uptake in ghsr-/- mice, suggesting marginally faster clearance in
ghsr-/- mice. Therefore, in vivo pharmacokinetics of [1-Nal4, Lys5(4-[18F]-FB)]G-7039
were independent of GHSR1a expression.
It is possible that the minimally differential uptake of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 in
the heart may be a function of GHSR1a expression; however, specificity could not be
confirmed. While GHSR1a expression is abundant in the hearts of wt mice, we were unable
to detect it using [1-Nal4, Lys5(4-[18F]-FB)]G-7039, leading us to conclude that [1-Nal4,
Lys5(4-[18F]-FB)]G-7039 uptake is not a surrogate measure of GHSR1a expression. PET
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dynamic images confirmed that the probe was being cleared within the first hour after
injection. Signal was visible in the liver but not the kidneys, suggesting the probe was
mainly excreted through the liver and intestinal system which is consistent with previous
studies using a lipophilic tracer81,83.
Binding of [1-Nal4, Lys5(4-FB)]G-7039 in tissues of ghsr-/- mice can be explained by either
non-specific binding, or probe reserve bound to circulating proteins. [1-Nal4, Lys5(4FB)]G-7039 was unable to discern receptor expression even though we discovered there
were differences by fluorescence microscopy. Uptake is independent of plasma ghrelin
levels and, although not significant, a slight positive trend was observed when relating
GHSR1a expression to cardiac uptake of [1-Nal4, Lys5(4-FB)]G-7039.
This molecule’s lipophilicity causes it to be highly insoluble in conventional clinical
injection vehicles (eg. saline) and contributed to non-specific binding to glass, plastic and
metal surfaces. As such, it was solubilized in 100% ethanol and diluted as necessary down
to <5% in saline upon injection.

4.6 Post-Mortem Tissue Staining of Metabolic Markers
Post-mortem analysis confirmed expression of GHSR1a in the fasted and fed mice, with
no differences observed. Receptor expression was also confirmed in the wt mice and,
unexpectedly, ghsr-/- mice as well, with cardiac expression of GHSR1a significantly
reduced, but still detectable, in ghsr-/- mice. The fatty acid transporter CD36 has been found
to bind synthetic growth hormone secretagogues (GHSs)108,109, which may explain nonspecific binding of Cy5-ghrelin in the ghsr-/- mice. Even after 12 h of fasting compared to
rats fed ad libitum, others have not noted changes to GHSR1a mRNA expression110. It is
unknown what an appropriate fasting time would be to observe changes to cardiac GHSR1a
expression. Circulating ghrelin levels are decreased in patients with HF76 and GHSR1a
levels in the heart are elevated77, so it has been suggested that increases in GHSR1a
expression are attempts to compensate for reduced ghrelin signaling. We were unable to
determine any relationship between circulating ghrelin and GHSR1a expression in normal
mice. Observable changes to receptor expression may only occur in a pathologic state such
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that receptor expression responds to ligand availability, where expression is increased
when the ligand is scarce.
Interestingly, cardiac ghrelin levels were elevated in fed mice sacrificed 1 h post-injection,
while circulating levels exhibited a similar (non-significant) trend. This is unexpected
because circulating ghrelin is usually elevated in a fasted state. However, ghrelin is
produced and secreted locally by cardiomyocytes74. We also found that circulating ghrelin
levels were not correlated with cardiac ghrelin expression, possibly indicating that cardiac
ghrelin regulation is independent of the peripheral system. The regulatory mechanisms
behind cardiac ghrelin secretion are not currently understood.
The expression of the insulin-dependent glucose transporter GLUT4 was reduced in fasted
mice as compared to fed. This is consistent with expectations111, as in a fasted state insulin
secretion is downregulated and ghrelin levels are elevated, further suppressing insulin
secretion.
Differences were not observed in SERCA2a between wt and ghsr-/- mice indicating that
GHSR1a does not influence cytosolic Ca2+ handling in a healthy state. GLUT4 and CD36
expression were also unaffected in healthy ghsr-/- mice, suggesting that the
ghrelin/GHSR1a axis is not integral to metabolism in healthy hearts even under temporary
fasting conditions. Prolonged fasting has been demonstrated to tease out the differences in
expression of these transporters. For example, decreased GLUT4 mRNA and increased
CD36 expression in rats fasted for 46 h has been reported112.
In HF, ghrelin has been shown to restore cardiac energy balance by reversing the switch
from lipids to glucose as the primary substrate to reflect a similar metabolic profile to that
of healthy hearts113. This is possibly because one of the downstream mechanisms of
GHSR1a activation is a decrease in lipid oxidation (which is present in HF)114. Initially
switching to glucose is meant to be oxygen sparing, but under chronic conditions, it is
detrimental because the metabolic demand exceeds the energy that can be supplied,
particularly in an anaerobic state where glucose metabolism is uncoupled from the Krebs
cycle and the electron transport chain14. We did not observe differences in ghrelin or
GLUT4 between wt and ghsr-/- mice, whereas both were elevated in fed mice; therefore, it
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is possible that the ghrelin/GHSR1a axis works to maintain cardiac energy balance instead
of impacting cardiac metabolism.
Imaging and biodistribution studies revealed probe uptake in the lungs of both wt and
ghsr-/- mice, so we evaluated pulmonary GHSR1a expression. Notably, again, GHSR1a
expression was detected in ghsr-/- mice. It is unknown if this is due to pulmonary expression
of CD36 as this was not evaluated. Potter et al.84 found similarly high lung uptake and
postulated that this was due to lack of specific binding due to high lipophilicity, which is
likely the same explanation for our findings. Aside from studies in developmental
physiology in rats that showed GHSR1a expressed in lungs115 and cancer studies, there
have also been reports of pulmonary GHSR1a expression in mice116. Pulmonary expression
has been documented in human tissue117, but was much less than myocardial expression85.
There is evidence that GHSR1a is expressed in alveolar macrophages118, where it is thought
to play a protective role. However, our histology analysis did not display presence of
alveolar macrophages in either group. This leads us to believe that the lung uptake observed
in this study is most likely due to non-specific distribution.
The morphology of the lung tissue appeared the same in both groups, leading to the
conclusion that unstressed ghsr-/- mice did not exhibit phenotypic differences in pulmonary
structure.

4.7 Future Directions
In vitro stability experiments show that [1-Nal4, Lys5(4-[18F]-FB)]G-7039 is a stable
structure over time. It should be noted that stability was tested in 25% human serum, which
did not account for metabolism in the liver and other organs. In vivo metabolite studies
testing whole blood and urine at various time-points can help to elucidate effects of
clearance tissues like the liver and kidneys and can also provide indications of the types of
metabolites, and clearance routes, allowing for modifications to structure to improve in
vivo investigations.
In vitro characterization showed good binding and activation of GHSR1a, so future studies
should focus on improving the probe’s properties to be more of a favourable in vivo agent,
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by generating a peptidomimetic library to elucidate possible formulations. In future
developments, reducing the lipophilicity of GHSs and achieving a binding affinity in the
picomolar range are important for in vivo implementation.
It would also be useful to model tracer kinetics in vivo to evaluate how the tracer binds and
to generate a receptor distribution map in the heart. It would be prudent to use a larger
animal model to visualize the heart (eg. rats) especially because there are established rat
models of GHSR1a knockout and cardiomyopathy. Software is available to model
pharmacokinetics and arterial blood can be sampled while imaging to acquire the arterial
input function (AIF) to measure regional probe uptake in the heart119. To generate
quantitative data of the probe flux: 1) from plasma to tissue, 2) association of free ligand
with receptor, and 3) ligand dissociation from receptor (Figure 15) can be quantified using
time activity curves from the tissue of interest and a reference region lacking the receptor.
Kinetic modelling will provide an estimation of the in vivo binding potential of the ligand.
Others have shown that graphical analysis is useful in quantifying enzymatic binding of
11

C-rolipram in rat myocardium, showing that it is possible to measure tracer distribution

in the rodent heart120.

Figure 15. Compartmental model using a reference tissue to quantify probe flux.
Future experiments should also look to address differences in ghrelin levels and to
potentially determine whether the ghrelin/GHSR1a axis contributes to cardiac metabolism.
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In this pursuit, mice should be fasted for longer and fed mice should be fasted prior to
feeding and then followed with tracer injection so that ghrelin levels are controlled for.
Moreover, Cy5-ghrelin binding in ghsr-/- mice should be addressed, by evaluating the
fluorescent probe for CD36 binding. Also, binding of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 to
CD36 has not been evaluated, but has been reported with the synthetic GHS hexarelin, so
it would be appropriate to test this.
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5

Conclusions and Significance

This study provides insight into probe development for imaging GHSR1a. The PET probe
[1-Nal4, Lys5(4-[18F]-FB)]G-7039 demonstrated in vitro stability and strong affinity for the
ghrelin receptor. It was characterized in vivo and did not demonstrate specific accumulation
in the heart. In vitro analysis of probe specificity determined that binding was independent
of receptor expression, which was confirmed by in vivo studies in wt and receptor-knockout
mice. Ex vivo biodistribution comparing specificity and effects of nutritional state showed
that uptake was independent of circulating ghrelin levels induced by fasting. High uptake
in the clearance pathways indicated probe elimination through hepatobiliary and renal
clearance. In addition, PET imaging in wt and ghsr-/- mice immediately post-injection was
unable to discriminate receptor expression, thus specificity of [1-Nal4, Lys5(4-[18F]-FB)]G7039 could not be confirmed.
Despite the strides made in imaging research for HF, distinguishing early pathogenesis and
understanding disease mechanisms remain unsolved concerns. Advances in therapeutic
approaches have emphasized the necessity for early recognition of heart failure which can
improve symptoms and quality of life, reduce disease progression rates, reduce hospital
admission rates, and increase survival. Ex vivo biodistribution and in vivo imaging data
acquired in mice represent a step towards characterizing a suitable GHSR1a PET tracer.
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Appendices
Appendix A. [1-Nal4, Lys5(4-[18F]-FB)]G-7039 Pre-SOP synthesis method
All the reagents and solvents used for radiosynthesis were purchased from Sigma-Aldrich
unless otherwise stated.

18

F-fluoride was produced via the

18

O(p,n) 18F reaction in a GE

PETtrace 880 cyclotron at Lawson Health Research Institute for desired radiotracer
synthesis. GE Tracer Lab FXN was used to prepare and purify [18F]fluorobenzoic Acid
([18F]FBA) Post-SOP.
As described in Scheme 1, [18F]FBA was prepared manually. Aqueous [18F]fluoride
solution was trapped on the Sep-Pak AccellTM plus carbonated QMA light cartridge. 1 mL
of acetonitrile/H2O (80/20; v/v) solution containing potassium carbonate (0.0015mmol, 2.5
equivalents) and kryptofix 2.2.2 (0.016mmol, 2.8 equivalents) was used to elute
[18F]fluoride into the reaction vial (Scheme 1ai). The solvent was removed azeotropically
in vacuum under the helium flow at 50°C. [18F]fluoride was dried three times by adding 1
mL of anhydrous acetonitrile respectively under the above condition. 400 μL of anhydrous
DMSO containing 0.0057 mmol, 1.9 equivalents mg of 4-(Tert-butoxycarbonyl)-N,N,Ntrimethylbenzenammonium triflate salt was added into dried [18F]F- under helium
atmosphere (Scheme 1aii). The reaction vial was sealed and heated at 120°C for 10 min.
At the same temperature and conditions, 1 mL of aqueous HCl (5 M) was added into
reaction vial and allowed to react for 5 min. The reaction mixture was heated 3 min at
100°C for hydrolysis of ester and then cooled down to 40°C. 2.5 mL of H2O was added to
dilute the reaction mixture. The product was trapped on Sep-Pak C18 light cartridge
(Waters), pre-treated with 10 mL ethanol then 10 mL water, and washed with 2 mL of H2O.
The solution of [18F]FBA in 500 µL mL of acetonitrile was added into the vial containing
0.17 mmol NHS (N-Hydroxysuccinimide) and 0.23 mmol EDC (1-Ethyl-3-(3dimethylaminopropyl)carbodiimide). The reaction was performed at room temperature for
10 min and. 1 mL of 25-90% acetonitrile/H2O + 0.1% TFA mixture was added into the
reaction vial. The raw product was purified on semipreparative HPLC column. The solvent
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was removed at 36°C on V-10 evaporator to get dried [18F]SFB (46.5% radiochemical
yield, radiochemical purity >99%).
The solution of 9.29e-4 mmol, 1.0 equivalent mg of [1-Nal4]G-7039 in 100 μL acetonitrile
and 100 μL H2O was added into the above [18F]SFB vial and followed by the addition of 5
μL DIPEA (N,N-Diisopropylethylamine) (Scheme 1c). The reaction mixture was heated at
50-70 °C for 15 min. 200 ul DMF, 400 uL H2O, and100 ul acetonitrile μL H2O were added
into reaction vial after cooling down to room temperature. The reaction mixture was
purified in semipreparative column (25-90% acetonitrile + 0.1% TFA) to get [1-Nal4,
Lys5(4-[18F]-FB)]G-7039 (Radiochemical yield 52%, radiochemical purity >98% and
molar activity 116 MBq/µmol).
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Appendix B. Pre-SOP synthesis and biodistribution results

Pre-SOP synthesis
Using the Pre-SOP synthesis method yielded [1-Nal4, Lys5(4-[18F]-FB)]G-7039 with a
radiochemical yield of 29-63% (average 52%), a radiochemical purity of >98% and a molar
activity of 116 MBq/μmol after 140 min.

Biodistributions using Pre-SOP synthesis
Biodistribution pre-SOP is shown in Figure 16. In fasted mice, heart uptake of [1-Nal4,
Lys5(4-[18F]-FB)]G-7039 was highest in mice sacrificed 1 h and 4 h post-injection. At 1 h
uptake was 6.9  2.7 %ID/g, which was equivalent to the 4 h uptake of 6.9  2.6 %ID/g.
Heart uptake in fasted mice sacrificed 2 h post-injection was lower than animals sacrificed
1 h and 4 h post-injection (5.7  3.1 %ID/g in 2 h). Only one animal was sampled for fed
2 h uptake prior to changeover to the automated synthesis protocol, so a comparison could
not be made between fasted and fed groups for Pre-SOP synthesis. Therefore, it was
resolved that fasting mice prior to imaging and imaging within the first hour after probe
injection would be appropriate.
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Figure 16. Biodistribution of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 using Pre-SOP
synthesis method in female C57BL/6 mice
Fasted (A) mice were euthanized 1 h, 2 h, 4 h, and 6 h after injection with [1-Nal4, Lys5(4[18F]-FB)]G-7039. One fed (B) mouse was sampled at 2 h post-injection. Values are mean
%ID/g  SEM for each group. As shown in (A): *p<0.05 in lung vs all tissues (except liver,
pancreas and urine). **p<0.01 urine vs all tissues, #p<0.05 in pancreas at 1 h vs 4 h, and
urine at 1 h vs 2 h, ##p<0.01 in lungs at 1 h vs 4 h and 6h.
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Appendix C. Animal research ethics approval
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Appendix D. Primer pairs for genotyping GHSR1a
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